Cytovia Therapeutics Licenses Productivity-Boosting Manufacturing Technology for Its NK Engager Multifunctional Antibodies From ProteoNic Cytovia developing novel CAR NK cell therapy and NK engager antibodies for cancer August 12, 2020 09:04 ET | Source: Cytovia Therapeutics NEW YORK and LEIDEN, the Netherlands, Aug. 12, 2020 (GLOBE NEWSWIRE) — Cytovia Therapeutics, Inc (Cytovia), an emerging biopharmaceutical company developing…
Leiden, the Netherlands, March 28, 2019. ProteoNic Biotechnology BV today announced that it has licensed its 2G UNic™ technology for boosting recombinant protein production to the pharmaceutical company Bayer.
Under the agreement, Bayer gains non-exclusive, worldwide commercial rights for application of the technology to the development of its proprietary products. Financial details of the agreement were …
Leiden, the Netherlands, Feb 5, 2019. ProteoNic Biotechnology BV announces that it licensed its 2G UNic™technology for boosting recombinant protein production to Eli Lilly and Company.
Under the agreement, Lilly gains non-exclusive commercial rights for application of the technology to the development of proprietary products. Financial details of the agreement were…
Horizon Discovery Signs License Agreement with ProteoNic B.V. for the Provision of Expression Vectors Alongside Horizon Bioproduction Cell Lines
Cambridge, UK, 7 June 2016: Horizon Discovery Group plc (LSE: HZD) (“Horizon”), the world leader in the application of gene editing technologies including bioproduction cell lines, today announces it has entered into a non-exclusive Licensing Agreement with ProteoNic B.V. to provide the CHOGUN expression vector to customers alongside Horizon’s HD-BIOP3 GS Null CHO cell line as standard, providing a powerful and…
Aragen Bioscience Announces Licensing Agreement for Protein Production Technology from ProteoNic Biotechnology
Aragen Bioscience, Inc. (Aragen) announces that it has entered into an agreement with ProteoNic Biotechnology BV (ProteoNic) for the commercial use of ProteoNic’s 2G UNic™ recombinant protein production technology. Under the terms of the agreement, Aragen gains the rights to apply this technology to the development of recombinant cell lines with significantly enhanced commercial production levels compared to current methods. In combination with the value added services offered by Aragen, access to the technology will allow Aragen’s clients to increase manufacturing efficiency and reduce cost of goods for recombinant biologicals.
Leiden, the Netherlands, 23 January 2014 – ProteoNic BV, a leading provider of technology for recombinant protein production, will participate in an international consortium that has been awarded a EUR 7 million Framework Program 7 (FP7) Research Grant by the European Commission. The FP7 grant will support the development of novel enzymes for efficient production of antioxidants.
ProteoNic, the experts in vector design and protein production, presented an update on its recently launched 2G UNic™ (second generation) technology for improved biopharmaceutical recombinant protein production on 4 November 2013 at the Cell Culture & Bioprocessing Congress in London.
35th Symposium on Biotechnology for Fuels and Chemicals April 29 – May 2, 2013 Portland, OR, USA
ProteoNic has relocated its headquarters, expanding its facilities at the Leiden Bio Science Park, the Netherlands.
Leiden, Netherlands/Oxford, United Kingdom, March 7, 2013 – Dutch biotech company ProteoNic BV and Oxford Expression Technologies Ltd (OET), a leading provider of baculovirus-based protein expression products and services, have extended their partnership by signing a commercial license agreement. OET obtains the right to use ProteoNic’s UNic™ translation enhancing elements in its flashBAC™ system for third party recombinant protein production services. ProteoNic will provide technical support. Financial terms include upfront and royalty payments.